Pandox AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

As you might know, Pandox AB (publ) (STO:PNDX B) last week released its latest first-quarter, and things did not turn out so great for shareholders. Results showed a clear earnings miss, with kr1.5b revenue coming in 3.5% lower than what the analystsexpected. Statutory earnings per share (EPS) of kr0.58 missed the mark badly, arriving some 56% below what was expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the consensus forecast from Pandox's twin analysts is for revenues of kr7.58b in 2025. This reflects a credible 6.0% improvement in revenue compared to the last 12 months. Per-share earnings are expected to leap 40% to kr9.74. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr7.72b and earnings per share (EPS) of kr10.49 in 2025. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts.

Check out our latest analysis for Pandox

The consensus price target held steady at kr207, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Pandox's past performance and to peers in the same industry. We would highlight that Pandox's revenue growth is expected to slow, with the forecast 8.0% annualised growth rate until the end of 2025 being well below the historical 17% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 4.9% annually. Even after the forecast slowdown in growth, it seems obvious that Pandox is also expected to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at kr207, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have analyst estimates for Pandox going out as far as 2027, and you can see them free on our platform here.

You still need to take note of risks, for example - Pandox has 3 warning signs (and 1 which is potentially serious) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.